04/05/20 PRESS RELEASE – immediate BCG Vaccine Clinical Trial in response to Covid-19 pandemic TASK008 – A placebo-controlled adaptive randomized controlled trial Caption of press photo: TASK nurse injects the first participant, watched closely by study leader Dr Caryn Upton and Professor Andreas Diacon, founder and CEO of TASK. TASK has just injected the…
TASK is a social enterprise committed to developing, testing and progressing novelty medicines, vaccines and diagnostics in various medical therapeutic areas, most notably in anti-tuberculosis drugs, aimed at improving global health care.
Since its inception in 2005, TASK has grown exponentially and diversified into six distinct independent clinical research sites; a mycobacteriology bio-safety level 3 laboratory; a phase I to II clinical trial hospital with twenty-four beds; two registered dispensing pharmacies; a data management centre; regulatory, quality control and compliance office and a clinical research training academy.
Over the last 15 years, TASK has completed multiple research projects, many of global significance and contributed to progressing the scientific field of TB medicine and vaccine development, most notably with early bactericidal activity (EBA) studies and clinical trials that in part led to the registration of Bedaquiline.